Unusual Adverse Event With Vandetanib in Metastatic Medullary Thyroid Cancer
Sophie Duplomb(Hôpital de la Croix-Rousse), Christelle de la Fouchardière(Aix-Marseille Université), Tae‐Hee Cho(Lyon 1 Université), Amandine Benoit(Hôpital Pierre Wertheimer), Jean Louis Peix(Lyon 1 Université), Laura Mechtouff-Cimarelli(Hôpital Pierre Wertheimer), Olfa Derbel(Hôpital Edouard Herriot)
Cited by 7
Related Papers
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|1.3k
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset
|New England Journal of Medicine|2018|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
|New England Journal of Medicine|2012|863
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766